Cinolazepam
|
WikiDoc Resources for Cinolazepam |
|
Articles |
|---|
|
Most recent articles on Cinolazepam Most cited articles on Cinolazepam |
|
Media |
|
Powerpoint slides on Cinolazepam |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on Cinolazepam at Clinical Trials.gov Clinical Trials on Cinolazepam at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on Cinolazepam
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Patient resources on Cinolazepam Discussion groups on Cinolazepam Patient Handouts on Cinolazepam Directions to Hospitals Treating Cinolazepam Risk calculators and risk factors for Cinolazepam
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for Cinolazepam |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Cinolazepam[1] (marketed under the brand name Gerodorm)[2] is a drug which is a benzodiazepine derivative. It possesses anxiolytic, anticonvulsant, sedative and skeletal muscle relaxant properties. Due to its strong sedative properties, it is primarily used as an hypnotic. Cinolazepam is not approved for sale in the United States or Canada.
See also
References
- ↑ US Patent 4388313 Novel 3-hydroxy-1,4-benzodiazepine-2-ones and process for the preparation thereof
- ↑ Lannacher Romania (1999). "Gerodorm". Produse Gerot inregistrate in Romania (in Romanian). Archived from the original on 11 October 2006. Retrieved 17 August 2006.